

Derwent WPI
(c) 2006 The Thomson Corporation. All rights reserved.

0005361946 *Drawing available*

WPI Acc no: 1990-361470/

XRAM Acc no: C1990-157105

XRPX Acc No: N1990-275794

New HIV-NDK retrovirus and protein component - used in vaccines against immuno-deficiency disorders and in raising MAbs for retro-virus detection in vivo

Patent Assignee: INSERM INST NAT SANTE & RECH MED (INRM)

Inventor: BARRESINOU F; CHERMANN J C; DEVAUX C; REY F; SIRE J; SPIRE B

Patent Family (4 patents, 16 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 1990013630	A	19901115	WO 1990FR312	A	19900502	199048	B
FR 2646606	A	19901109	FR 19895914	A	19890503	199101	E
EP 471028	A	19920219	EP 1990908235	A	19900502	199208	E
JP 4507042	W	19921210	JP 1990507972	A	19900502	199304	E
			WO 1990FR312	A	19900502		

Priority Applications (no., kind, date): FR 19895914 A 19890503

Patent Details

Patent Number	Kind	Lan	Pgs	Draw	Filing Notes					
WO 1990013630	A	EN								
National Designated States,Original	CA JP US									
Regional Designated States,Original	AT BE CH DE DK ES FR GB IT LU NL SE									
EP 471028	A	EN								
Regional Designated States,Original	AT BE CH DE ES FR GB IT LI LU NL SE									
JP 4507042	W	JA	12		PCT Application	WO 1990FR312				
					Based on OPI patent	WO 1990013630				

Alerting Abstract WO A

A highly cytopathogenic HIV-NDK retrovirus (I), having a sequence given in the specification, is new. Also new are mutants of (I), fragments of it and methods for preparing a protein and/or enzyme of the virus.

USE/ADVANTAGE - The protein is useful as an agent in a vaccine for preventing immunodeficiency disorders. Monoclonal antibodies (Abs) raised against the protein antigen are useful for detecting the presence of the retroviral proteins in a subject.

USE/ADVANTAGE - In an example, to compare the cytopathogenicity of the HIV1-BRU isolate and HIV1-NDK, a serum containing differing dilutions of the supernatant of virus released from cells containing it used to infect MT4 cells. The presence of syncitia was determined in the cell culture 7 days after infection. The results illustrated that stocks of HIV1-NDK (diluted by 10 power(-7)) were capable of inducing syncitia formation whereas the prototype HIV1 diluted up to power(-3) times did not produce a cytopathic effect.

Title Terms /Index Terms/Additional Words: NEW; HIV; RETROVIRUS; PROTEIN; COMPONENT; VACCINE; IMMUNO; DEFICIENT; DISORDER; RAISE; RETRO; VIRUS; DETECT; VIVO